Sanofi and GlaxoSmithKline have begun clinical trials of their coronavirus vaccine ... Meanwhile GSK is producing the booster that reduces the amount of active ingredient necessary to produce ...

GSK and Sanofi think they could ... at preventing severe COVID-19 disease and asymptomatic infection. With an eye on countries' emerging plans for booster shots, the two companies will also ...

and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M ...

During the quarter, GSK did not record any sales from the COVID-19 booster vaccine, which was co-developed with Sanofi SNY. Core selling, general and administration (SG&A) costs rose 6% to £2.70 ...

rising to 100% after a booster dose (91). Neutralization titers were comparable to those observed in convalescent plasma from people who had recovered from COVID-19. Nucleic acid-based vaccines (DNA ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Cornell researchers have developed a new vaccine platform that could provide more robust, longer-lasting protection from both ...

Higher levels of long COVID were found in lower-income households. More than 1 million children may have been affected by long COVID as of 2023, new federal data published Monday suggests.

People are being urged to book one of the hundreds of thousands of COVID booster appointments still available before the NHS scales down its vaccination programme and focuses on at-risk patients.

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...